Trial Profile
Linagliptin Inpatient Trial: A Randomized Controlled Trial on the Safety and Efficacy of Linagliptin (Tradjenta) Therapy for the Inpatient Management of General Surgery Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary) ; Insulin; Insulin aspart; Insulin glargine; Insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Linagliptin Surgery Trial
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 13 Jun 2017 Results (n=251) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 08 Mar 2017 Status changed from recruiting to completed.